ICU

ICU Medical Announces First Quarter 2024 Results

Retrieved on: 
星期二, 五月 7, 2024
Use, ICU, Sale, Bank statement, ICU Medical, ICUI, GAAP, SAN

SAN CLEMENTE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024.

Key Points: 
  • SAN CLEMENTE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024.
  • First quarter 2024 revenue was $566.7 million, compared to $568.6 million in the same period in the prior year.
  • Adjusted diluted earnings per share for the first quarter of 2024 was $0.96 as compared to $1.74 for the first quarter of 2023.
  • Adjusted EBITDA was $78.8 million for the first quarter of 2024 as compared to $102.0 million for the first quarter of 2023.

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
星期一, 五月 6, 2024
PSMA, FDA, Net, University, Part, DLBCL, EDT, City, CRS, Safety, PIN, University of Miami, Pancreatic cancer, Infrared spectroscopy correlation table, Research, Hematology, Insurance, PR, MD, Growth, ICU, Rituximab, Follicular lymphoma, ADC, Patient, Therapeutic index, Sarcoma, S&M, Diffuse large B-cell lymphoma, NHL, Cytokine release syndrome, Marketing, IIT, Advertising, Therapy, NSCLC, Spacecraft, AXL, Lung cancer, Pharmaceutical industry

Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.

Key Points: 
  • Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.
  • Net product revenues were $17.8 million for the first quarter 2024, compared to $19.0 million for the first quarter 2023.
  • R&D expenses were $25.7 million for the first quarter 2024, compared to $38.4 million for the first quarter 2023.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2024 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance

Retrieved on: 
星期一, 五月 6, 2024
Nursing, Medical Devices, FDA, Health, Managed Care, Biotechnology, Food, Water, ICU, Patient, Dialysis, Medicine, Movement, Chair, Medical device

Outset has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the United States.

Key Points: 
  • Outset has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the United States.
  • "With the FDA's clearance of TabloCart with prefiltration, we have delivered features to the Tablo Hemodialysis System that increase the flexibility for nurses and health systems to serve patients from the ICU to the bedside,” said Leslie Trigg, Chair and CEO of Outset Medical.
  • It comes in two versions: one with added storage and another featuring water prefiltration capabilities, meeting diverse clinical needs.
  • Key features of TabloCart include:
    Versatile prefiltration: With its three customizable prefiltration options, TabloCart is designed to adapt to varying water conditions and also features a booster pump to increase incoming water pressure.

Interviews Available: Mother/Daughter, Mother/Son and Father/Son Nurse Duos Call Providence Mission Hospital Home

Retrieved on: 
星期一, 五月 6, 2024
ICU, Friends, Patient, Nursing, Family, Parent, Hospital, Infant, SICU

The parents on each team have worked at the hospital for decades and inspired their children to join the nursing ranks.

Key Points: 
  • The parents on each team have worked at the hospital for decades and inspired their children to join the nursing ranks.
  • Kris is a spine/brain critical care nurse; went back-to-school to become a nurse when Kayla was a baby.
  • Kayla was born at Mission Hospital and grew up answering the phones in the ICU where she now works.
  • Jessica, known as her mom's twin, worked at Mission Hospital in high school; she is an ICU nurse that shares patients with her mom.

University of Phoenix College of Nursing Alumna and Faculty Publish Article on Lived Experiences of Intensive Care Unit Nursing During Pandemic

Retrieved on: 
星期五, 五月 3, 2024
Health, Continuing, University, Nursing, Education, Pain, Nurse education, COVID, MSN, Learning, The Linacre Quarterly, University of Phoenix, Frailty, Navajo Nation, Conference, Research, Phoenix College, Caritas, ICU, MMIW, WCSI, Family, Patient, RN, College, Faculty, Data analysis, Philosophy, Student, COVID-19

University of Phoenix College of Nursing is pleased to highlight the recent publication by alumna Gloria Littlemouse, Ph.D. in Nursing, MSN, RN, WCSI Scholar, whose dissertation study informed an article, “Lived Experiences of ICU Nurses During COVID-19,” in the journal, The Linacre Quarterly.

Key Points: 
  • University of Phoenix College of Nursing is pleased to highlight the recent publication by alumna Gloria Littlemouse, Ph.D. in Nursing, MSN, RN, WCSI Scholar, whose dissertation study informed an article, “Lived Experiences of ICU Nurses During COVID-19,” in the journal, The Linacre Quarterly.
  • The article was co-authored by Littlemouse with Patricia Finch Guthrie, Ph.D., RN, faculty and Project Chair, and Margaret Kroposki, Ph.D., RN, associate faculty, both in the Doctor of Nursing Practice Program, College of Nursing.
  • Watson's theory of Caring Science guided the study to ensure a holistic interpretation of the data.
  • University of Phoenix College of Nursing accredited programs prepare students for the delivery of quality, compassionate care, and recognizes that flexible and relevant educational programs are essential to prepare students for contemporary nursing practice.

Hall of Fame U.S. Soccer Player Kristine Lilly to Join Hundreds of MNA Nurses and Healthcare Professionals at the State House May 8 for Advocacy Day During National Nurses Week

Retrieved on: 
星期五, 五月 3, 2024
National Nurses United, Organization, Kristine Lilly, Silver, Sport, Book, Medfield, Massachusetts, RNS, Workplace violence, Commonwealth, Olympic Games, Statehouse, Workplace, Legislature, ICU, Speech, Grand Staircase, Gold, Patient, Legislation, Athlete, Football, Lilly, Multimedia, MNA, Health, Female, Excellence, Nursing

BOSTON, May 3, 2024 /PRNewswire/ -- Hundreds of nurses and healthcare professionals will flood the State House on May 8, marking National Nurses Week with a Day of Advocacy focused on protecting patients, healthcare workers, and essential healthcare services. They will be joined by Kristine Lilly, one of the most accomplished athletes in women's soccer history, a teamwork expert, and an advocate for pay equity in women's sports.

Key Points: 
  • The Massachusetts Nurses Association will also release its annual "State of Nursing in Massachusetts" survey ahead of Advocacy Day, on Monday, May 6.
  • It will provide critical insight into care quality and nursing practice challenges, and the legislative solutions nurses say will ensure safe, accessible patient care.
  • "I am excited to join hundreds of MNA nurses and healthcare professionals as they urge their elected officials to protect patients, workers, and essential healthcare services," Kristine Lilly said.
  • Lilly was inducted into the US Olympic Hall of Fame in 2012 and the US Soccer Hall of Fame in 2014.

Recovering Patient Reunites with Penn Highlands DuBois Trauma Team Who Saved His Life

Retrieved on: 
星期三, 四月 24, 2024
Trauma center, Disability, Trauma Team, Abdomen, Rib cage, Injury, EMS, Weather, Hospital, Trauma, Travel, Emergency medical services, Death, MD, Bleeding, Rib, Life, FACS, ICU, Nursing, Liver, Patient, Physician, Level, General surgery, Human, MHA, Emergency medical technician, Coma

He was transported to the Level II Trauma Center at Penn Highlands DuBois where the Trauma Team saved his life.

Key Points: 
  • He was transported to the Level II Trauma Center at Penn Highlands DuBois where the Trauma Team saved his life.
  • Richmond required extensive surgery,” explained Philip S. Vuocolo, MD, MHA, FACS, a board-certified acute-care and trauma surgeon at Penn Highlands General Surgery and Trauma Medical Director for Penn Highlands DuBois.
  • On April 23, 2024 during a meeting with the Trauma Team and emergency services personnel, they expressed gratitude to the team who saved his life.
  • “I am very thankful that we have such a skilled Trauma Team and Trauma Center in our region and I will never hesitate to travel from York to DuBois for my care.”
    Penn Highlands DuBois is accredited as a Level II Trauma Center by the Pennsylvania Trauma Systems Foundation.

As guidelines elevate stethoscope hygiene requirements, new technology may resolve pathogen transmission via touch

Retrieved on: 
星期四, 四月 18, 2024
World government, Fungal infection, System, HAI, Risk, Hospital, CDC, Diaphragm, MD, ICU, Environment, Hygiene, Patient, Stethoscope, Clean, LifePoint Health, Health, Infection, Nursing

This allows clinicians and health facilities to meet the new 2024 guidelines from the US Centers for Disease Control and Prevention (CDC) that elevate concern with stethoscope transmission of pathogens through touch, the foundation of Healthcare Associated Infections (HAI).

Key Points: 
  • This allows clinicians and health facilities to meet the new 2024 guidelines from the US Centers for Disease Control and Prevention (CDC) that elevate concern with stethoscope transmission of pathogens through touch, the foundation of Healthcare Associated Infections (HAI).
  • Previously, the stethoscope was classified as a non-critical item, similar to bed railings and countertops, despite stethoscopes touching US patients more than 5 billion times per year.
  • The DiskCover System uses a wall-mounted, motion-activated dispenser that is loaded with a Clean Cassette®.
  • Each cassette maintains 420 disk covers in an aseptic (clean) environment until it is applied to a stethoscope.

SeaStar Medical Reports 2023 Financial Results and Provides a Business Update

Retrieved on: 
星期三, 四月 17, 2024
Mortality, FDA, Nephrology, Risk, Nephron, Partnership, Hepatorenal syndrome, Acute kidney injury, ICU, White, AKI, Chronic kidney disease, Monocyte, Heart failure, SCD, Dialysis, CRRT, CKRT, KRT, Inflammation, Safety, Insurance, Clinical study design, Therapy, Clinical trial, G&A, Sepsis, University, HDE, Survival rate, Neutrophil, Acute respiratory distress syndrome, Patent, Cardiorenal syndrome, European Journal, Physician, Manuscript, Bank statement, Standard of care, Pharmaceutical industry

DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.

Key Points: 
  • DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.
  • “Lastly, I’m pleased that we have filed our Form 10-K for 2023, which includes restated 2022 financial statements,” said Mr. Schlorff.
  • Mr. Green brings to SeaStar Medical extensive financial experience at public medical device and therapeutics companies.
  • The Company reported cash of $176,000 as of December 31, 2023, compared with $47,000 as of December 31, 2022.

Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole

Retrieved on: 
星期一, 四月 15, 2024
University, Safety, Risk, Nausea, ICU, Fungal infection, Incidence, Patient, SOC, Fusarium, Aes, Clutch (eggs), Standard of care, Pharmaceutical industry

LONDON, April 15, 2024 (GLOBE NEWSWIRE) --  Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced topline results from the OPERA-S study: a Phase 2 safety and tolerability study in lung transplant patients receiving inhaled opelconazole monotherapy as prophylaxis against pulmonary aspergillosis. Opelconazole is an investigational inhaled triazole antifungal being developed to prevent and treat pulmonary aspergillosis. In this study, opelconazole was generally well tolerated with a low incidence of drug-related adverse events (AEs) and a low incidence of treatment-limiting respiratory AEs. Importantly, there were no dose reductions or discontinuations of opelconazole prophylaxis or of immunosuppressant medications due to opelconazole-related drug-drug interactions (DDIs). Despite the expected small numbers, there was evidence of prevention of pulmonary aspergillosis and of eradication in the lungs of both Aspergillus and Candida colonization with opelconazole monotherapy.

Key Points: 
  • In this study, opelconazole was generally well tolerated with a low incidence of drug-related adverse events (AEs) and a low incidence of treatment-limiting respiratory AEs.
  • Importantly, there were no dose reductions or discontinuations of opelconazole prophylaxis or of immunosuppressant medications due to opelconazole-related drug-drug interactions (DDIs).
  • Importantly, respiratory AEs related to opelconazole were rarely treatment-limiting, leading to discontinuation in two out of 65 opelconazole patients.
  • Three patients in the study died: one in the opelconazole group (1.5%) and two in the SOC group (6%).